

## Contact person



**Mario Linimeier:** Managing Partner,  
Head of Portfolio Management



**Martina Beran:** Head of Sales

“

**„Research leads to impact.  
Impact leads to growth.“**

From innovation to  
outperformance

4 tailwind factors for  
biotech

1. **Innovative biotech stocks**
2. **Focus on small and mid-cap companies**
3. **Focus on leading developers of innovative therapies**
4. **Scientists as portfolio managers**
5. **Successful investment history and outperformance**


**Emerging patent cliff** puts pressure on Big Pharma, forcing them to seek out innovative players, hence increasing M&A activity

**Strong fundamentals:** Product advances are completely uncorrelated with macro factors; demand for essential medicines and therapies largely independent of economic cycles

**Health as a macro trend:** Demographic change and technological progress are leading to increased importance of the sector


**Low valuation levels:** Small and mid caps in the biotech segment – valuations often below cash

## Performance since launch



As of December 31, 2025; Source: vwd; Price indices in EUR; The previous day's closing prices were used to calculate the index performance and convert exchange rates. As the fund invests primarily in North America, the time difference was taken into account. Fund: Performance calculation based on gross value performance (BVI method). The front-end load (for investment and reinvestment) was not taken into account, nor were individual costs such as custody fees. Taking into account the front-end load and custody fees, the performance would be lower. Past performance is not an indicator of future performance and is no guarantee of future success.

## Annual rolling performance



Calculation based on gross performance (BVI method), i.e. without taking the front-end load into account. Past performance is not a reliable indicator of future performance. Gross performance (BVI method) takes into account all costs incurred at fund level (e.g., management fees), while net performance also takes into account the front-end load. Additional costs may be incurred individually at customer level (e.g., custody fees, commissions, and other fees). Model calculation (net): An investor wants to purchase shares for EUR 1,000. With a maximum front-end load of 5%, they must pay a one-time fee of EUR 50 upon purchase. In addition, custody fees may apply, which reduce the performance. The custody fees are based on your bank's price and service list. Source: Anevis Solutions GmbH, own representation

## 5 therapy areas with particular market potential

- Cancer
- Rare diseases
- Cardiometabolic diseases
- Autoimmune diseases
- CNS diseases

## Awards



## Further information

### LinkedIn



### Newsletter



### Opportunities

- Participation in the global growth of the healthcare market
- Portfolio of carefully selected companies
- Focus on developers of innovative therapies
- Expertise of an interdisciplinary team of experts with scientific backgrounds

Disclaimer: <https://medicalstrategy.de/datenschutz/disclaimer-mbh>

### Risks

- Price risk
- Misjudgments in investment selection are possible
- Specific risks of drug development
- Market risk
- Liquidity risks
- Currency risks